- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
- Clearmind Applies to Cease Being a Reporting Issuer in Canada
- Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
- Clearmind Medicine CEO Issues Letter to Shareholders
- Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
- Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
- Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
- Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
More ▼
Key statistics
On Friday, Clearmind Medicine Inc (CMND:NAQ) closed at 1.22, 32.54% above the 52 week low of 0.9205 set on Jan 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.28 |
---|---|
High | 1.31 |
Low | 1.19 |
Bid | 1.23 |
Offer | 1.25 |
Previous close | 1.29 |
Average volume | 5.28m |
---|---|
Shares outstanding | 3.17m |
Free float | 2.92m |
P/E (TTM) | -- |
Market cap | 3.87m USD |
EPS (TTM) | -30.92 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼